NKGen Appoints Alzheimer’s Expert Bruce Miller To Advisory Board, Leads Scientific Development

NKGen Biotech announced that it has appointed renowned neurologist Dr. Bruce L. Miller to its Scientific Advisory Board. The clinical-stage company, which is developing autologous and allogeneic natural killer (NK) cell therapies, said Dr. Miller will contribute deep scientific and clinical insight, particularly in neurodegenerative diseases such as Alzheimer’s disease and frontotemporal dementia.

Dr. Miller is a distinguished professor of neurology at the University of California, San Francisco, where he leads the Edward and Pearl Fein Memory and Aging Center and founded the Global Brain Health Institute. Over several decades, he has helped advance understanding of dementia through research into brain-behavior relationships, molecular and genetic drivers of disease, and precision medicine strategies for tauopathies and FTD-related disorders.

“We are honored to welcome Dr. Miller to our Scientific Advisory Board. His global leadership in neurodegeneration research and his long-standing contributions to the Alzheimer’s and FTD fields bring a level of expertise that will meaningfully inform our clinical and scientific priorities as we continue to execute our development strategy, including our ongoing Phase 2 clinical trial evaluating our autologous NK cell therapy candidate, troculeucel, in individuals with moderate Alzheimer’s disease. We also look to leverage his expertise to further explore the use of troculeucel in FTD, where we have seen some very promising early signals in patients treated under expanded access,” said Paul Y. Song, M.D., Chairman and CEO of NKGen Biotech. “

He is one of the most widely published experts in the field, with more than 2,000 peer-reviewed papers and several influential books to his name, including The Behavioral Neurology of Dementia and Frontotemporal Dementia. His work has helped define the clinical and biological distinctions among Alzheimer’s disease, FTD, and other neurodegenerative conditions.

Dr. Miller has also played major roles in international research collaborations, including initiatives supported by the Tau Consortium and the Bluefield Foundation, which focus on developing therapies for tau-driven diseases and progranulin-related FTD. NKGen said his appointment strengthens its scientific leadership as it continues to advance its cell therapy pipeline.